(Q64955321)

English

PIK3CA Mutations and Neoadjuvant Therapy Outcome in Patients with Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: A Sequential Analysis.

scientific article published on 29 October 2018

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PMC publication ID

1 July 2019

http://europepmc.org/abstract/PMC/6310726

PIK3CA Mutations and Neoadjuvant Therapy Outcome in Patients with Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: A Sequential Analysis. (English)

1 reference

Europe PubMed Central

PMC publication ID

1 July 2019

http://europepmc.org/abstract/PMC/6310726

author name string

Youjeong Seo

1

1 reference

Europe PubMed Central

PMC publication ID

1 July 2019

http://europepmc.org/abstract/PMC/6310726

Yeon Hee Park

2

1 reference

Europe PubMed Central

PMC publication ID

1 July 2019

http://europepmc.org/abstract/PMC/6310726

Jin Seok Ahn

3

1 reference

Europe PubMed Central

PMC publication ID

1 July 2019

http://europepmc.org/abstract/PMC/6310726

Young-Hyuck Im

4

1 reference

Europe PubMed Central

PMC publication ID

1 July 2019

http://europepmc.org/abstract/PMC/6310726

Seok Jin Nam

5

1 reference

Europe PubMed Central

PMC publication ID

1 July 2019

http://europepmc.org/abstract/PMC/6310726

Soo Youn Cho

6

1 reference

Europe PubMed Central

PMC publication ID

1 July 2019

http://europepmc.org/abstract/PMC/6310726

Eun Yoon Cho

7

1 reference

Europe PubMed Central

PMC publication ID

1 July 2019

http://europepmc.org/abstract/PMC/6310726

publication date

29 October 2018

1 reference

Europe PubMed Central

PMC publication ID

1 July 2019

http://europepmc.org/abstract/PMC/6310726

Journal of breast cancer

1 reference

Europe PubMed Central

PMC publication ID

1 July 2019

http://europepmc.org/abstract/PMC/6310726

21

1 reference

Europe PubMed Central

PMC publication ID

1 July 2019

http://europepmc.org/abstract/PMC/6310726

4

1 reference

Europe PubMed Central

PMC publication ID

1 July 2019

http://europepmc.org/abstract/PMC/6310726

382-390

1 reference

Europe PubMed Central

PMC publication ID

1 July 2019

http://europepmc.org/abstract/PMC/6310726

copyright license

Creative Commons Attribution-NonCommercial 4.0 International

1 January 2018

1 reference

April 2022 Public Data File from Crossref

copyright status

0 references

Linking molecular diagnostics to molecular therapeutics: targeting the PI3K pathway in breast cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/30607159

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The PIK3CA gene is mutated with high frequency in human breast cancers.

1 reference

https://pubmed.ncbi.nlm.nih.gov/30607159

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Exploiting the PI3K/AKT pathway for cancer drug discovery

1 reference

https://pubmed.ncbi.nlm.nih.gov/30607159

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/30607159

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

An integrative genomic and proteomic analysis of PIK3CA, PTEN, and AKT mutations in breast cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/30607159

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

PIK3CA mutation associates with improved outcome in breast cancer.

1 reference

https://pubmed.ncbi.nlm.nih.gov/30607159

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Lapatinib monotherapy in patients with relapsed, advanced, or metastatic breast cancer: efficacy, safety, and biomarker results from Japanese patients phase II studies.

1 reference

https://pubmed.ncbi.nlm.nih.gov/30607159

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

American Society of Clinical Oncology/College Of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/30607159

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Lapatinib plus capecitabine in treating HER2-positive advanced breast cancer: efficacy, safety, and biomarker results from Chinese patients.

1 reference

https://pubmed.ncbi.nlm.nih.gov/30607159

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

PI3K pathway activation results in low efficacy of both trastuzumab and lapatinib

1 reference

https://pubmed.ncbi.nlm.nih.gov/30607159

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Comprehensive molecular portraits of human breast tumours

1 reference

https://pubmed.ncbi.nlm.nih.gov/30607159

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The predictive role of phosphatase and tensin homolog (PTEN) loss, phosphoinositol-3 (PI3) kinase (PIK3CA) mutation, and PI3K pathway activation in sensitivity to trastuzumab in HER2-positive breast cancer: a meta-analysis.

1 reference

https://pubmed.ncbi.nlm.nih.gov/30607159

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Outcome impact of PIK3CA mutations in HER2-positive breast cancer patients treated with trastuzumab

1 reference

https://pubmed.ncbi.nlm.nih.gov/30607159

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update

1 reference

https://pubmed.ncbi.nlm.nih.gov/30607159

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Direct inhibition of PI3K in combination with dual HER2 inhibitors is required for optimal antitumor activity in HER2+ breast cancer cells

1 reference

https://pubmed.ncbi.nlm.nih.gov/30607159

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase I/II study of pilaralisib (SAR245408) in combination with trastuzumab or trastuzumab plus paclitaxel in trastuzumab-refractory HER2-positive metastatic breast cancer.

1 reference

https://pubmed.ncbi.nlm.nih.gov/30607159

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Intrinsic subtypes, PIK3CA mutation, and the degree of benefit from adjuvant trastuzumab in the NSABP B-31 trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/30607159

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

PIK3CA mutations are associated with decreased benefit to neoadjuvant human epidermal growth factor receptor 2-targeted therapies in breast cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/30607159

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Association of PIK3CA Mutation Status before and after Neoadjuvant Chemotherapy with Response to Chemotherapy in Women with Breast Cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/30607159

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The predictive and prognostic role of phosphatase phosphoinositol-3 (PI3) kinase (PIK3CA) mutation in HER2-positive breast cancer receiving HER2-targeted therapy: a meta-analysis

1 reference

https://pubmed.ncbi.nlm.nih.gov/30607159

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The clinical value of HER-2 overexpression and PIK3CA mutations in the older breast cancer population: a FOCUS study analysis.

1 reference

https://pubmed.ncbi.nlm.nih.gov/30607159

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

New insights on PI3K/AKT pathway alterations and clinical outcomes in breast cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/30607159

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

PIK3CA mutations are associated with reduced pathological complete response rates in primary HER2-positive breast cancer: pooled analysis of 967 patients from five prospective trials investigating lapatinib and trastuzumab.

1 reference

https://pubmed.ncbi.nlm.nih.gov/30607159

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

PIK3CA mutations in HER2-positive breast cancer: an ongoing conundrum.

1 reference

https://pubmed.ncbi.nlm.nih.gov/30607159

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Impact of somatic PI3K pathway and ERBB family mutations on pathological complete response (pCR) in HER2-positive breast cancer patients who received neoadjuvant HER2-targeted therapies.

1 reference

https://pubmed.ncbi.nlm.nih.gov/30607159

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Neoadjuvant buparlisib plus trastuzumab and paclitaxel for women with HER2+ primary breast cancer: A randomised, double-blind, placebo-controlled phase II trial (NeoPHOEBE).

1 reference

https://pubmed.ncbi.nlm.nih.gov/30607159

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.4048/JBC.2018.21.E48

1 reference

Europe PubMed Central

PMC publication ID

1 July 2019

http://europepmc.org/abstract/PMC/6310726

PMC publication ID

1 reference

Europe PubMed Central

PMC publication ID

1 July 2019

http://europepmc.org/abstract/PMC/6310726

PubMed publication ID

1 reference

Europe PubMed Central

PMC publication ID

1 July 2019

http://europepmc.org/abstract/PMC/6310726

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q64955321&oldid=1891188117"